🔍

PGHL - P & G Health Ltd

📊 NSE: PGHL 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 10:49

📢 Recent Corporate Announcements

PGHL Declares ₹160 Interim Dividend Including ₹50 Special Dividend

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 06 Feb 2026, 05:58 PM

Procter & Gamble Health Limited has announced a substantial interim dividend of ₹160 per equity share for the financial year 2025-26. This total payout includes a one-time special dividend of ₹50 per share, signaling a significant cash distribution to shareholders. The record date for determining eligibility is set for February 12, 2026. Shareholders must ensure their tax documents and PAN details are updated by February 10, 2026, to avoid higher TDS deductions.

Declared an interim dividend of ₹160 per equity share with a face value of ₹10 each.
The payout includes a one-time special dividend component of ₹50 per share.
The record date for determining shareholder eligibility is February 12, 2026.
Standard TDS of 10% applies for resident shareholders with PAN; 20% for those without.
Submission deadline for tax exemption forms (15G/15H) is February 10, 2026.

💡 Investors interested in the dividend should ensure they hold the stock before the record date of February 12, 2026. Existing shareholders should promptly submit tax-related declarations to the RTA by February 10 to optimize their net payout.

PGHL Q3 Net Profit Drops 14.6% to ₹77.6 Cr; Declares Massive ₹160 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 02:53 PM

Procter & Gamble Health Limited (PGHL) reported a 20.7% YoY growth in revenue to ₹373.86 crore for the quarter ended December 31, 2025. Despite revenue growth, net profit declined by 14.6% YoY to ₹77.59 crore due to a significant 40% surge in total expenses, particularly in raw materials and employee benefits. To reward shareholders, the board declared a substantial interim dividend of ₹160 per share, which includes a ₹50 special dividend. The record date for this payout is February 12, 2026.

Revenue from operations increased by 20.7% YoY to ₹373.86 crore from ₹309.77 crore.
Net profit for the quarter fell 14.6% YoY to ₹77.59 crore compared to ₹90.90 crore in the previous year.
Declared an interim dividend of ₹160 per equity share, including a one-time special dividend of ₹50.
Total expenses rose sharply to ₹269.40 crore from ₹192.04 crore in the corresponding quarter last year.
Nine-month net profit for the period ended December 2025 stands at ₹232.31 crore, up from ₹190.01 crore YoY.

💡 Investors should focus on the high dividend yield offered by the ₹160 payout, while keeping a close watch on rising operating costs that impacted quarterly margins. The stock is likely to attract yield-seeking investors ahead of the February 12 record date.

PGHL Q3 Sales Up 21% to ₹368 Cr; Declares ₹160 Interim Dividend per Share

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 02:48 PM

Procter & Gamble Health Limited (PGHL) reported a strong 21% year-on-year growth in sales, reaching ₹368 crores for the quarter ended December 31, 2025. The company's Profit After Tax (PAT) stood at ₹78 crores, driven by robust brand fundamentals and new product innovations like Livogen Iron Gummies. A major highlight for shareholders is the declaration of an interim dividend of ₹160 per equity share, which includes a ₹50 special dividend. This performance underscores the company's leadership in the vitamins, minerals, and supplements (VMS) category in India.

Sales for the quarter ended December 31, 2025, rose 21% YoY to ₹368 crores.
Profit After Tax (PAT) for the quarter reached ₹78 crores.
Declared an interim dividend of ₹160 per share, including a one-time special dividend of ₹50.
Growth supported by new innovations including Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
Strong top-line momentum maintained from the first half of the financial year 2025-26.

💡 Investors should take note of the significant dividend payout and strong revenue growth as signs of a healthy cash-rich business. The stock remains a solid play in the VMS segment with high brand equity in products like Neurobion and Evion.

PGHL Declares Rs 160 Interim Dividend; Q3 Revenue Up 20.7% YoY to Rs 373.86 Cr

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 06 Feb 2026, 02:44 PM

Procter & Gamble Health Limited has declared a substantial interim dividend of Rs 160 per share, which includes a one-time special dividend of Rs 50. For the quarter ended December 31, 2025, revenue grew 20.7% YoY to Rs 373.86 crore, although net profit declined 14.6% to Rs 77.59 crore due to higher operating expenses. The nine-month performance remains strong with a net profit of Rs 232.31 crore compared to Rs 190.01 crore in the previous year. The record date for the dividend is fixed as February 12, 2026.

Declared an interim dividend of Rs 160 per equity share, including a Rs 50 special dividend
Q3 Revenue from operations rose 20.7% YoY to Rs 373.86 crore from Rs 309.77 crore
Net profit for the quarter dipped to Rs 77.59 crore from Rs 90.90 crore YoY due to increased expenses
Nine-month net profit increased to Rs 232.31 crore from Rs 190.01 crore in the corresponding previous period
Record date for dividend eligibility is February 12, 2026, with payment by March 4, 2026

💡 Investors seeking high dividend yields should ensure they hold shares before the February 12 record date. While quarterly margins were pressured by costs, the overall nine-month growth and high payout ratio remain attractive for long-term holders.

PGHL Declares ₹160 Interim Dividend; Q3 Revenue Rises 20.7% to ₹373.86 Crore

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 06 Feb 2026, 02:40 PM

Procter & Gamble Health Limited (PGHL) has declared a significant interim dividend of ₹160 per share, which includes a ₹50 special dividend. For the quarter ended December 31, 2025, the company reported a 20.7% YoY increase in revenue to ₹373.86 crore. However, net profit for the quarter saw a decline of 14.6% YoY to ₹77.59 crore due to increased operational expenses. Despite the quarterly profit dip, the nine-month profit for the period ending December 2025 remains strong at ₹232.31 crore, up from ₹190.01 crore in the previous year.

Declared interim dividend of ₹160 per equity share, including a one-time special dividend of ₹50.
Revenue from operations grew to ₹373.86 crore in Q3 FY26 from ₹309.77 crore in Q3 FY25.
Net profit for the quarter stood at ₹77.59 crore, down from ₹90.90 crore in the corresponding previous quarter.
Nine-month net profit showed healthy growth, reaching ₹232.31 crore compared to ₹190.01 crore YoY.
Record date for dividend eligibility is fixed as February 12, 2026, with payment by March 4, 2026.

💡 Investors should ensure they hold shares by the February 12 record date to benefit from the high dividend payout. While quarterly margins were pressured, the overall nine-month growth and strong dividend policy reflect a stable financial position.

PGHL Declares Rs 160 Interim Dividend; Q3 Revenue Rises 20.7% to Rs 373.9 Crore

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 06 Feb 2026, 02:38 PM

Procter & Gamble Health Limited (PGHL) has announced a significant interim dividend of Rs 160 per share, which includes a one-time special dividend of Rs 50. For the quarter ended December 31, 2025, the company reported a 20.7% YoY increase in revenue to Rs 373.86 crore. However, quarterly net profit declined by 14.6% YoY to Rs 77.59 crore, impacted by a sharp rise in employee benefits and other operational expenses. Despite the quarterly profit dip, the nine-month performance remains robust with a 22.3% growth in net profit to Rs 232.31 crore.

Declared interim dividend of Rs 160 per equity share, including a Rs 50 special dividend.
Q3 Revenue from operations grew 20.7% YoY to Rs 37,386 lakhs.
Nine-month Net Profit increased by 22.3% YoY to Rs 23,231 lakhs.
Total expenses for the quarter rose significantly to Rs 26,940 lakhs from Rs 19,204 lakhs in the previous year.
Record date for dividend eligibility is fixed as February 12, 2026, with payment by March 4, 2026.

💡 Investors should ensure they hold shares by the February 12 record date to qualify for the substantial dividend payout. While quarterly margins were pressured by higher costs, the strong nine-month growth and high dividend yield remain attractive for income-seeking investors.

PGHL Submits Routine SEBI Compliance Certificate for Quarter Ended December 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Jan 2026, 09:10 PM

Procter & Gamble Health Limited (PGHL) has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that the company's Registrar and Transfer Agent, Kfin Technologies Limited, has processed all security dematerialization requests for the quarter ended December 31, 2025. This is a standard administrative procedure to ensure that physical shares converted to electronic form are correctly recorded with the depositories (NSDL and CDSL). The company has confirmed that these details were furnished to the stock exchanges within the prescribed timelines.

Compliance certificate issued for the quarter ended December 31, 2025.
Confirmation received from Registrar and Transfer Agent, Kfin Technologies Limited.
Adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Verified reporting of dematerialized securities to both BSE and NSE.

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's financial performance and upcoming earnings announcements.

PGHL Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 12:14 PM

Procter & Gamble Health Limited (PGHL) has announced the closure of its trading window for all directors and designated employees starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's quarterly financial results. The window will remain shut until 48 hours after the publication of the unaudited financial results for the quarter ending December 31, 2025. This is a standard regulatory procedure and does not indicate any fundamental change in the company's operations.

Trading window closure begins on January 1, 2026
Applies to all Directors and designated employees of the company
Closure relates to the financial results for the quarter ending December 31, 2025
Window will reopen 48 hours after the official publication of financial results

💡 No action is required as this is a routine regulatory filing. Investors should await the announcement of the specific date for the Q3 financial results.

View All PGHL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company delivered sales of INR 319 Cr in Q2 FY26, representing a 3% YoY growth. For the 9-month fiscal year ended March 31, 2025, sales reached INR 918 Cr, up 8% compared to the same period in the previous year. The Vitamins, Minerals, and Supplements (VMS) segment remains the core driver, with Neurobion reach expanding 1.4x over 5 years.

Geographic Revenue Split

While specific regional percentage splits are not disclosed, the company is aggressively targeting rural India, aiming to increase coverage and leverage e-commerce to broaden portfolio availability across the country.

Profitability Margins

Net profit margins expanded by 200 basis points over the last 5 years. For the 9-month fiscal ended March 31, 2025, Profit After Tax (PAT) was INR 234.41 Cr, representing a 25.5% net margin. Q2 FY26 PAT stood at INR 89 Cr, up 8% YoY.

EBITDA Margin

Historical data shows operating profit (OPBDIT/OI) at 17.4% in CY2018, up from 13.5% in CY2017. Recent structural profit growth was reported at 27% for the 9-month fiscal year 2024-25, driven by productivity efforts and sales growth.

Capital Expenditure

Not disclosed in absolute INR Cr for future periods; however, the company focuses on 'maximizing return on assets' and has seen Return on Equity (ROE) increase 3x over the past 5 years (with a 34% increase specifically noted in recent trends).

Credit Rating & Borrowing

The company maintains a strong financial profile with a credit rating of [ICRA]AA (Stable). It operates with a net cash position and zero total debt (Total Debt/TNW of 0.0), resulting in negligible borrowing costs.

⚙️ Operational Drivers

Raw Materials

Specific raw materials include active pharmaceutical ingredients (APIs) for Vitamins (E, B12, B1, B6), minerals, and supplements. While exact cost percentages per material are not disclosed, the 'Vitamins' segment represents a high product concentration for the company.

Import Sources

The company leverages the global supply chain of its parent, The Procter & Gamble Company (P&G), and historically sourced technology and materials from Merck KGaA (Germany) following the 2018 acquisition.

Key Suppliers

Key suppliers include P&G global affiliates and Merck KGaA (under historical business transfer agreements).

Capacity Expansion

Current capacity is not disclosed in MT; however, the company has transformed its manufacturing operations and go-to-market model over the last 5 years to support a 1.4x increase in absolute sales volume.

Raw Material Costs

Raw material costs are managed through a 'productivity muscle' that delivered over INR 40 Cr in savings during the 2024-25 fiscal year. These savings are reinvested into product superiority and brand building.

Manufacturing Efficiency

Efficiency is driven by 'continuous technology upgrades' from the parent company, P&G, focusing on process efficiencies and cost-effectiveness in production.

Logistics & Distribution

The company has added nearly 100,000 new stores for its Neurobion brand over 5 years, indicating a massive expansion in distribution logistics and retail activation.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved through the 'Integrated Growth Strategy' which focuses on five vectors: Portfolio, Superiority, Productivity, Constructive Disruption, and an Agile Organization. Specific actions include expanding rural coverage, leveraging e-commerce, and launching innovations in the VMS category. The company achieved INR 40 Cr in productivity savings to fuel reinvestment in brand communication and retail execution.

Products & Services

Over-the-counter (OTC) and prescription medicines including vitamins, minerals, and supplements (VMS), and nasal decongestants.

Brand Portfolio

Neurobion, Livogen, Polybion, Evion, Nasivion, and Seven Seas.

New Products/Services

New innovations in the VMS category contributed to the 3% sales growth in Q2 FY26; specific revenue contribution percentages for new launches are not disclosed.

Market Expansion

Plans involve increasing 'Coverage in Rural Areas' and broadening the digital shelf via e-commerce to reach more healthcare practitioners (HCPs) and consumers.

Market Share & Ranking

The company is a major player in the Indian VMS market, with Neurobion being a leading brand in the vitamin B segment.

Strategic Alliances

The company benefits from a technology license and support agreement with its parent, The Procter & Gamble Company (P&G), providing access to cutting-edge R&D and manufacturing processes.

🌍 External Factors

Industry Trends

The healthcare sector is shifting toward preventative care and supplements. The industry is evolving through digital health and e-commerce expansion. PGHL is positioning itself by strengthening its 'digital shelf' and increasing engagement with healthcare practitioners (HCPs).

Competitive Landscape

Key competitors include other major pharmaceutical and FMCG players in the VMS and OTC space; competition is based on brand reach, doctor prescriptions, and retail availability.

Competitive Moat

The moat is built on 'superior brand legacy' (e.g., Neurobion, Evion) and access to P&G's global 'advanced technology' and 'productivity muscle.' These are sustainable due to high consumer trust and the high cost of entry for pharmaceutical manufacturing and distribution.

Macro Economic Sensitivity

The company is sensitive to rural consumption trends; IMF projects India's economy to grow by 6.8% in 2024 and 6.5% in 2025, which is expected to support private consumption and demand for health products.

Consumer Behavior

There is an increasing consumer focus on 'holistic health' and 'preventative supplementation,' which directly benefits the company's VMS-heavy portfolio.

Geopolitical Risks

Trade barriers or global supply chain disruptions could impact the import of specialized pharmaceutical ingredients required for their VMS portfolio.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily governed by the Drugs and Cosmetics Act and the Drug Price Control Order (DPCO), which regulates the ceiling prices of essential medicines, directly impacting the pharmaceutical portfolio's revenue growth.

Environmental Compliance

The company integrates environmental sustainability into its 'Citizenship' efforts, seeking to reduce the footprint of operations and enable consumers to do the same.

Taxation Policy Impact

The effective tax rate for FY 2024-25 was approximately 24.8% (Tax of INR 77.21 Cr on PBT of INR 311.62 Cr).

Legal Contingencies

The company reported 'Nil' complaints regarding sexual harassment during the fiscal year. Other specific pending litigation values in INR are not disclosed in the provided documents.

⚠️ Risk Analysis

Key Uncertainties

Regulatory changes in drug pricing (DPCO) and high product concentration in the Vitamin category (VMS) are the primary uncertainties that could impact margins by 5-10% if more products are brought under price control.